secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265755
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo reports Q3 2025 net loss $20.3M; FDA open to accelerated BLA for LX2006; raised $154M equity
--------------------------------------------------------------------------------

- FDA agreed to consider pooling ongoing Phase I/II LX2006 data with pivotal trial data for BLA; co-primary endpoint earlier than 12 months okayed.
- FDA approved comparability between HEK293 and Sf9 manufacturing processes for LX2006; Sf9 process endorsed for pivotal study.
- LX2006 interim data: 18-23% mean LVMI improvement at 6-12 months in abnormal-baseline patients; 2.0-point mean mFARS improvement (n=16).
- Enrollment complete for LX2020 HEROIC-PKP2 Phase I/II (10 dosed); substantive data update expected January 2026.
- Cash, equivalents, investments $122.8M at Sep 30, 2025; plus $153.8M net from October equity offering funds operations into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/0001193125-25-265755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312525265755/lxeo-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer